OR WAIT null SECS
August 01, 2023
Insights into current practice of global pharma labeling, including shortcomings and potential improvements.
July 31, 2023
While clinical registries are a valued source of longitudinal, real-world data, registries also provide expanded options for research and advancing randomized clinical trials. Understanding when and how to use registries in these use cases is quite nuanced and mandates a targeted approach and innovative expertise. In this video, we dive deep into the expanded use of registries as external control arms in clinical trials.
January 04, 2023
Reactions and top-of-mind concerns regarding digitalization and the collection and review of data used to shape patient-centric healthcare.
November 29, 2022
Pharmaceutical Executive, in collaboration with Biofourmis, organized a roundtable of experts from various groups to discuss how digital medicine and pharmaceuticals are changing the trajectory of what drug development and clinical care look like together, with an emphasis on partnerships within digital health.
October 20, 2022
August 19, 2022
Richard Young, Vice President of Strategy, Vault CDMS and Tim Davis, Vice President of Strategy, MyVeeva for Patients, discuss the future of digital trials and their impact in the industry.
August 16, 2022
Imaging is an integral part of many clinical studies, particularly in the fields of oncology and ophthalmology. Learn why imaging and centralized review are essential for clinical trials, how to address challenges that arise in these studies, and the advantages of partnering with MERIT in this video.
May 24, 2022
Defining what Gross-to-Net mean and why it is important to Life Sciences companies; Identify who in the company benefits in utilizing information from GTN; Get insights to successfully define and manage GTN process
May 12, 2022
In this video Akeel Williams, VP of Strategy and Operations, Manufacturer Solutions, explains how GoodRx uses data to continuously improve its platform for patients and providers.
May 06, 2022
As life science organizations continue to leverage both real world data [RWD] and real-world evidence [RWE] in the product approval landscape, a more nuanced understanding of both RWD and RWE is needed. Given the expansive types of data available now, understanding which data set is needed and how it should be analyzed is decidedly valuable. Our expert provides basic tenets for consideration